Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jennifer Fokas, MD, and Minali Nigam, MD, neurologists at Northwestern Medicine with specialized training in headache medicine, join the podcast to discuss current challenges and evolving strategies in the management of cluster headache. They highlighted the substantial burden of disease, particularly among patients with chronic cluster headache, and the diagnostic difficulties that arise from overlap with migraine features. They emphasized the importance of recognizing cranial autonomic symptoms as key distinguishing features, along with typical attack duration and circadian or seasonal patterns. The conversation also covered practical approaches to acute and preventive treatment, including high-flow oxygen via non-rebreather mask, subcutaneous sumatriptan, bridge therapies, and preventive options such as high-dose verapamil and, in selected cases, lithium. The physicians also review emerging and adjunctive options while noting limitations in evidence, indications, and access. They concluded by underscoring the need for clinician preparedness and tailored therapy to enable more assertive and appropriate management of cluster headache. Looking for more Headache and Migraine discussion? Check out the NeurologyLive® Headache and Migraine focus page.Episode Breakdown: 1:54 – Biggest unmet need in cluster headache 5:01 – Importance of multimodal acute management and access issues 7:39 – Neurology News Minute  10:03 – Emerging and experimental therapies 13:03– Preventive options and special situations 17:51 – Key clinical takeaway: preparation and access to therapies The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Zilganersen, First Treatment for Alexander Disease FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug FDA Approves Apitegromab for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.REFERENCE1. Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI. Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(1):117-124. doi:10.1111/head.14021

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Aaron Zelikovich, MD, a neuromuscular physician at Lenox Hill Hospital, part of Northwell Health, joins the podcast to discuss the emerging conversation around dual therapy in spinal muscular atrophy (SMA). As disease-modifying treatments continue to reshape survival and long-term outcomes, Zelikovich examines whether combining SMN-targeted approaches could provide additional benefit, while emphasizing that evidence supporting dual therapy remains limited and significant barriers to studying it persist. The conversation explores clinician and patient interest in combination treatment, insurance and access challenges, and what current evidence suggests about adding therapy after gene replacement, particularly in children who are not meeting expected motor milestones. Zelikovich also discusses the need for better biomarkers to guide treatment decisions, the changing natural history of adult SMA, and why stronger real-world data and prospective research will be critical to determining whether dual therapy ultimately has a place in SMA care. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.Episode Breakdown: 1:05 – Clinical perspectives and current controversy surrounding dual therapy in SMA 2:40 – Discussing dual therapy expectations and uncertainty with patients and families 4:35 – Evidence guiding when clinicians should consider adding a second therapy 6:20 – Neurology News Minute  8:55– Developing better biomarkers to guide long-term SMA treatment decisions 11:15 – Research needed to evaluate dual therapy and adult SMA outcomes 13:35 – Moving the dual therapy conversation forward through patient-clinician partnerships The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Clears Roche's Single-Biomarker Elecsys pTau217 Blood Test for Alzheimer Disease FDA Extends Deramiocel Review for Duchenne Muscular Dystrophy After HOPE-3 Amendment AHA/ASA Issue New Guideline for Adult Stroke Rehabilitation and Recovery Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Pezhman Roohani, MD, neurologist and medical director of the teleneurology and telestroke program at Allina Health, joins the podcast to discuss the emerging role of GLP-1 receptor agonists across neurology. Roohani outlines where these therapies may have the greatest impact, highlighting stroke prevention, neurodegenerative diseases, idiopathic intracranial hypertension, and other areas being explored as researchers look beyond their established metabolic effects. The conversation also examines what recent Alzheimer disease trial results mean for the future of GLP-1 research, including the potential importance of prevention and identifying patient subgroups most likely to benefit. Roohani discusses key cautions surrounding long-term use, muscle loss, nutrition, and lifestyle modification, as well as practical considerations when counseling patients. He closes by highlighting unanswered research questions and potential applications in neuroinflammation, traumatic brain injury, and addiction. Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.Episode Breakdown: 1:15 – Neurologic conditions showing the greatest promise for GLP-1 therapies 4:15 – GLP-1s in neurodegeneration following recent Alzheimer trial results 7:35 – Key cautions and limitations surrounding long-term GLP-1 use 9:35 – Neurology News Minute  11:50– Counseling patients on lifestyle changes when initiating GLP-1 therapy 14:20 – Research priorities and emerging neurologic applications for GLP-1s The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: First-Ever Platform Trial for Progressive Supranuclear Palsy Enrolls Its Inaugural Participant FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.Episode Breakdown: 1:25 – Professional background and clinic overview 2:55 – What an effective multidisciplinary SMA care team looks like 5:12 – How disease-modifying therapies have changed SMA care 6:28 – Neurology News Minute  9:27 – Organizational and procedural challenges in coordinating care 11:52 – Why raising awareness about SMA is important & advice to clinicians 13:45 – Key message about SMA today  The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike. The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research. Episode Breakdown: 1:10 – Journey into neuro-oncology and career-defining experiences 4:50 – Mission and philosophy behind The G.L.O.B. 7:10 – Key themes readers can expect from the column 9:45 – Career lessons that shaped Dr. Gatson's clinical practice 16:30 – Vision for The G.L.O.B. and improving healthy literacy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In episode 171, “Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies,” Craig A. Erickson, MD, professor of psychiatry at Cincinnati Children’s Hospital, discussed the evolving landscape of Fragile X syndrome (FXS) care in honor of National Fragile X Syndrome Day. Erickson reviewed current challenges in recognizing and diagnosing FXS. He also underscored the importance of genetic testing and outlined key counseling points for families once a diagnosis is confirmed.Erickson, who also serves as the director of the Cincinnati Fragile X Research and Treatment Center, provided an overview of behavioral and neuropsychiatric management across the lifespan. He highlighted evidence-informed approaches for ADHD, irritability and aggression, and anxiety, as well as the critical role of early intervention and structured supports in adulthood. The discussion closed with a look at emerging therapeutics and how these advances may reshape clinical practice and long-term outcomes for individuals with FXS.Looking for more Genetic Disorders discussion? Check out the NeurologyLive® Genetic Disorders clinical focus page.Episode Breakdown: 1:25 – Challenges in recognizing and diagnosing Fragile X  3:25 – Genetic counseling and cascade testing after diagnosis  6:00 – Managing behavioral and neuropsychiatric symptoms  9:55 – News Minute  12:45 – Clinical management across the lifespan  17:12 – Emerging therapies and research priorities  21:17 – Why Fragile X awareness remains critical  The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea FDA Accepts NDA for Axsome Therapeutics’ AXS-12 for the Treatment of Cataplexy in Narcolepsy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Daniel Ontaneda, MD, PhD, professor of neurology at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses a recently published study in Neurology evaluating the application of the 2024 McDonald Criteria in individuals with nonspecific neurologic symptoms or incidental MRI findings. Using data from the CAHPS-MS study, Ontaneda explains how the revised diagnostic criteria perform in these previously understudied patient populations and what the findings may mean for earlier identification of multiple sclerosis. The conversation explores the rationale behind expanding the 2024 McDonald Criteria, the role of central vein sign and cerebrospinal fluid oligoclonal bands in improving diagnostic confidence, and how clinicians should approach patients who fall into a diagnostic gray zone. Ontaneda also discusses the practical application of the updated criteria, the importance of longitudinal follow-up, and how emerging biomarkers may continue to refine MS diagnosis in the years ahead.  Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page.Episode Breakdown: 1:15 – Why the 2024 McDonald Criteria expanded diagnostic eligibility 4:30 – Applying the criteria in nonspecific symptom presentations 6:20 – Clinical relevance of symptom patterns and MRI findings 8:40 – Using biomarkers to improve diagnostic confidence 11:25 – Neurology News Minute  13:55– Interpreting dissemination in time with updated criteria 15:45 – Future validation of emerging MS diagnostic biomarkers The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Advisory Committee Schedules Meeting to Review Deramiocel's BLA in Duchenne Muscular Dystrophy FDA Clears PoNS Device for Stroke Rehabilitation, Expanding Neurostimulation Beyond MS Indication FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Grace Gombolay, MD, associate professor of pediatrics at Emory University School of Medicine and director of the Pediatric Neuroimmunology and Multiple Sclerosis Program at Children's Healthcare of Atlanta, joins Varun Kannan, MD, assistant professor of pediatrics in the Department of Neurology at Emory University School of Medicine and Children's Healthcare of Atlanta, for a discussion on acute disseminated encephalomyelitis (ADEM), a rare inflammatory demyelinating syndrome that remains an important diagnostic consideration in pediatric neuroimmunology. The conversation provides a practical overview of how clinicians should recognize ADEM, distinguish it from conditions such as multiple sclerosis, MOG antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), and approach treatment in the absence of FDA-approved therapies. Gombolay and Kannan review the clinical and radiographic hallmarks of ADEM, the role of MRI and antibody testing in the diagnostic workup, and current treatment strategies involving corticosteroids, IVIG, and plasma exchange. They also discuss long-term outcomes, the evolving relationship between ADEM and MOGAD, emerging biomarkers such as neurofilament light chain and cytokine profiling, and common misconceptions that can complicate diagnosis and management in clinical practice. Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page.Episode Breakdown: 1:15 – Recognizing the clinical and imaging features of ADEM 3:30 – Distinguishing ADEM from MS, MOGAD, and NMOSD 7:20 – Current treatment approaches and management strategies 10:10 – Neurology News Network  12:40 – Long-term outcomes and monitoring after recovery 15:55 – Emerging biomarkers and improving diagnostic precision 19:10 – Preventing future attacks and reducing relapse risk 21:10 – Remaining research gaps and unanswered questions in ADEM The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.Episode Breakdown: 1:10 – PROCEED trial efficacy in patients with prior preventive failures 5:10 – Safety and tolerability findings for bocunebart 6:30 – Coadministration data with ubrogepant and clinical implications 8:30 – Neurology News Network  10:50 – Rationale for combining PACAP and CGRP-targeted therapies 13:40 – Key considerations for future phase 3 development The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice. The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care. Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page.Episode Breakdown: 1:15 – Why formal insomnia combination treatment guidance was needed 2:45 – Defining concurrent CBT-I and pharmacotherapy approaches 4:35 – Evidence supporting CBT-I as foundational insomnia treatment   7:15 – Situations where combination therapy may improve patient outcomes 7:50 – Neurology News Network  10:20 – Patient-specific factors influencing insomnia treatment selection 12:30 – Barriers involving CBT-I access, cost, and real-world implementation 16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.